⚠ Tool for educational and informational purposes only — not investment advice or a recommendation to buy or sell. Investing carries risk of capital loss. Read the full disclaimer.
GTBP — GT Biopharma, Inc.
Last scan (Sept. 18, 2026): price $7.49, RSI 68.22, relative volume 0.27x, MACD 🟢 Yes, score 65.45.
It's in a bullish underlying trend (above its 200-day average), with an RSI of 68.22 in a neutral zone. The daily MACD confirms short-term bullish momentum. Relative volume of 0.27x is below normal — little interest today. The analysts' average target price implies +901.3% upside — one of the score's strongest signals.
Price chart
GTBP
Price: $7.16 · RSI (14): 33.27 · Rel. volume: 2.37x · Breakout: No
- Current price: ($7.16) — solid white line — the latest available closing price.
- Target price: ($75.0) — dashed green line — average 12-month target price from analysts covering the stock.
- Quarter low: ($4.91) — dotted orange line — the lowest price over the last ~3 months, as a recent support reference.
You can zoom by dragging a rectangle over the chart, or with your mouse wheel. Double-click to reset the view.
What analysts say
GTBP
GT Biopharma, Inc.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target…
- Buy 1
- Hold 0
- Sell 0
Average target price: $75.0 (+947.5% vs. current price) · range $75.0 – $75.0
Healthy Moderate Attention No data
Total market value of the company (price × shares outstanding).
P/E (trailing): compares the stock's price with its earnings per share over the last 12 months — how many times that earning is being paid for.
Low: the market pays little for each dollar of earnings. Could be a value opportunity, or a sign the market expects little growth.
P/E (forward): same as P/E, but using analysts' estimated earnings per share for the next year.
Same as P/E, using estimated future earnings.
PEG: the P/E divided by the expected earnings growth rate — relates how expensive the stock is to how fast it's expected to grow.
Between 1 and 2: the price is roughly aligned with expected growth.
Debt/Equity: how much debt the company carries per dollar of shareholder equity — measures how leveraged the balance sheet is.
Not enough data.
Net margin: what percentage of each dollar of revenue ends up as net profit, after all costs.
Low margin: the business has little cushion if costs rise.
Dividend: what percentage of the stock's price is paid out in cash to shareholders each year.
Doesn't pay dividends: reinvests earnings into growth instead of distributing them.
Beta: how volatile the stock is compared to the overall market (S&P 500 = 1.0).
Moves similarly to the overall market.
General reference ranges, do not vary by sector. Third-party data; may be incomplete. Not investment advice.
💰 Financial Statements (last 3 quarters)
💰 Financial Statements (last 3 quarters)
What this chart shows
- Japanese candlesticks: green when the period's close is higher than its open, red when it's lower.
- Volume: bars colored the same as the candle for that period.
- RSI (14): bottom line with reference levels at 70 (overbought) and 30 (oversold) — the same indicator the daily scanner uses.
- Dotted line on top: the high of the last 20 periods, the same reference the scanner uses to detect breakouts.
Third-party market data, for informational purposes. Not investment advice — read the disclaimer.